Investigating how to convert heart cells to repair damage after heart attacks
Post-transcriptional mechanisms of direct cardiac reprogramming
This study is looking for new ways to help heal heart damage after a heart attack by turning certain heart cells into new heart muscle cells, and it's for anyone interested in better treatments for heart recovery.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10947754 on NIH RePORTER |
What this research studies
This research focuses on finding ways to regenerate heart muscle cells lost during heart attacks by transforming cardiac fibroblasts into induced cardiomyocyte-like cells. The team will explore the role of specific proteins and genetic factors that influence this transformation, particularly looking at post-transcriptional mechanisms that affect gene expression. By utilizing advanced techniques like ATAC-seq, they aim to identify how these factors can be manipulated to enhance cell reprogramming. The ultimate goal is to develop a more effective treatment for heart damage that could improve recovery and heart function.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have experienced a heart attack and are seeking new treatment options for heart regeneration.
Not a fit: Patients with non-cardiovascular conditions or those who have not experienced heart damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that restore heart function in patients who have suffered heart attacks.
How similar studies have performed: Other research has shown promise in similar approaches to cardiac regeneration, indicating potential for success in this area.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Xie, Yifang — Univ of North Carolina Chapel Hill
- Study coordinator: Xie, Yifang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.